이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Cellectis 관리

관리 기준 확인 2/4

Cellectis' CEO는 Andre Choulika, Jan1999 에 임명되었습니다 의 임기는 25.42 년입니다. 총 연간 보상은 $ 876.60K, 99.8% 로 구성됩니다. 99.8% 급여 및 0.2% 보너스(회사 주식 및 옵션 포함). 는 € 1.83M 가치에 해당하는 회사 주식의 1.02% 직접 소유합니다. 1.83M. 경영진과 이사회의 평균 재임 기간은 각각 3.9 년과 7.3 년입니다.

주요 정보

Andre Choulika

최고 경영자

US$876.6k

총 보상

CEO 급여 비율	99.8%
CEO 임기	25.5yrs
CEO 소유권	1.4%
경영진 평균 재임 기간	4yrs
이사회 평균 재임 기간	7.3yrs

최근 관리 업데이트

Recent updates

We Think Some Shareholders May Hesitate To Increase Cellectis S.A.'s (EPA:ALCLS) CEO Compensation

May 26

Is Cellectis (EPA:ALCLS) Using Debt Sensibly?

May 17

These Analysts Think Cellectis S.A.'s (EPA:ALCLS) Sales Are Under Threat

Mar 08

Cellectis (EPA:ALCLS) Is In A Strong Position To Grow Its Business

Feb 16

Are Institutions Heavily Invested In Cellectis S.A.'s (EPA:ALCLS) Shares?

Jan 12

Analysts Are Betting On Cellectis S.A. (EPA:ALCLS) With A Big Upgrade This Week

Dec 08

CEO 보상 분석

Andre Choulika 의 보수는 Cellectis 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$78m
Dec 31 2023	US$877k	US$875k	-US$109m
Sep 30 2023	n/a	n/a	-US$72m
Jun 30 2023	n/a	n/a	-US$77m
Mar 31 2023	n/a	n/a	-US$91m
Dec 31 2022	US$744k	US$744k	-US$91m
Sep 30 2022	n/a	n/a	-US$63m
Jun 30 2022	n/a	n/a	-US$78m
Mar 31 2022	n/a	n/a	-US$99m
Dec 31 2021	US$879k	US$879k	-US$86m
Sep 30 2021	n/a	n/a	-US$129m
Jun 30 2021	n/a	n/a	-US$121m
Mar 31 2021	n/a	n/a	-US$113m
Dec 31 2020	US$1m	US$1m	-US$37m
Sep 30 2020	n/a	n/a	-US$79m
Jun 30 2020	n/a	n/a	-US$66m
Mar 31 2020	n/a	n/a	-US$67m
Dec 31 2019	US$1m	US$1m	-US$102m

보상 대 시장: Andre 의 총 보상 ($USD 876.60K )은 French 시장( $USD 534.67K ).

보상과 수익: 회사가 수익성이 없는 동안 Andre 의 보상이 증가했습니다.

CEO

Andre Choulika (59 yo)

25.5yrs

테뉴어

US$876,597

보상

Dr. Andre Choulika, Ph.D. is the Founder of Cellectis S.A. and has been its Chief Executive Officer since 1999 and served as its Chairman since 2011 until November 5, 2020. He is the Director of Cellectis...

리더십 팀

이름	위치	테뉴어	보상	소유권
Andre Choulika	Co-Founder	25.5yrs	US$876.60k	1.41% $ 1.9m
David j. Sourdive	Deputy CEO	no data	US$557.84k	0.43% $ 561.7k
Arthur Stril	Interim Chief Financial Officer	less than a year	데이터 없음	0.012% $ 15.7k
Valerie Cros	Principal Financial Officer & Principal Accounting Officer	2.6yrs	데이터 없음	데이터 없음
Jean Epinat	Chief Technological Officer	no data	데이터 없음	데이터 없음
Philippe Duchateau	Chief Scientific Officer	12.5yrs	데이터 없음	0.060% $ 79.2k
Marie-Bleuenn Terrier	General Counsel & Secretary of the Board of Directors	11.5yrs	데이터 없음	0.042% $ 56.1k
Pascalyne Wilson	Director of Communications	no data	데이터 없음	데이터 없음
Kyung Nam-Wortman	Executive VP & Chief Human Resources Officer	3.7yrs	데이터 없음	0.016% $ 21.3k
Stephan Reynier	Chief Regulatory & Pharmaceutical Compliance Officer	no data	데이터 없음	0.027% $ 36.2k
Steven Doares	Senior VP of US Manufacturing & Site Head of the Raleigh	4yrs	데이터 없음	0.017% $ 22.9k
Mark Frattini	Chief Medical Officer	3.9yrs	데이터 없음	0.024% $ 31.2k

4.0yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: ALCLS 의 관리팀은 경험 ( 3.9 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Andre Choulika	Co-Founder	25.5yrs	US$876.60k	1.41% $ 1.9m
David j. Sourdive	Deputy CEO	24.5yrs	US$557.84k	0.43% $ 561.7k
Jean-Pierre Garnier	Independent Non-Executive Chairman	3.7yrs	US$97.34k	0% $ 0
Laurent Arthaud	Director	12.8yrs	데이터 없음	데이터 없음
Pierre Bastid	Independent Director	12.8yrs	US$97.34k	0.078% $ 102.4k
Rainer Boehm	Independent Director	7.1yrs	US$99.60k	0% $ 0
Dietger Niederwieser	Member of Clinical Advisory Board	7.3yrs	데이터 없음	데이터 없음
Kanti Rai	Member of Clinical Advisory Board	7.5yrs	데이터 없음	데이터 없음
Catherine Bollard	Member of Clinical Advisory Board	7.3yrs	데이터 없음	데이터 없음
Ola Landgren	Member of Clinical Advisory Board	7.3yrs	데이터 없음	데이터 없음
Marcela Maus	Member of Clinical Advisory Board	7.3yrs	데이터 없음	데이터 없음
Stephan Grupp	Member of Clinical Advisory Board	5.8yrs	데이터 없음	데이터 없음

7.3yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 이사회: ALCLS 의 이사회는 경험(평균 재직 기간 7.3 년)으로 간주됩니다.

Cellectis 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Cellectis S.A., Annual General Meeting, Jun 28, 2024

Cellectis Announces Chief Financial Officer Changes

Cellectis S.A. Announces Board Appointments

Less than half of directors are independent

Cellectis S.A., Annual General Meeting, Jun 27, 2023

Insufficient new directors

Recent updates

Cellectis Announces the Publication of A Scientific Article in Nature Communications

New minor risk - Profitability

First quarter 2024 earnings released: EPS: US$0.079 (vs US$0.49 loss in 1Q 2023)

Cellectis S.A. to Report Q1, 2024 Results on May 28, 2024

Cellectis S.A., Annual General Meeting, Jun 28, 2024

New major risk - Shareholder dilution

Cellectis Announces Chief Financial Officer Changes

Full year 2023 earnings released: US$1.92 loss per share (vs US$1.99 loss in FY 2022)

No longer forecast to breakeven

Cellectis S.A. to Report Q1, 2024 Results on May 09, 2024

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Cellectis S.A. Announces Board Appointments

New major risk - Shareholder dilution

New minor risk - Profitability

New major risk - Financial position

Third quarter 2023 earnings released: US$0.31 loss per share (vs US$0.63 loss in 3Q 2022)

Cellectis S.A. to Report Q3, 2023 Results on Nov 06, 2023

New major risk - Share price stability

Less than half of directors are independent

Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of A Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase ? Syndrome Type 1 (APDS1)

Second quarter 2023 earnings released: US$0.09 loss per share (vs US$0.42 loss in 2Q 2022)

Cellectis S.A. to Report Q2, 2023 Results on Aug 03, 2023

Cibus Global, Ltd. completed the acquisition of Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cellectis S.A., Annual General Meeting, Jun 27, 2023

Cellectis S.A. Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T- Cells at ASGCT 2023

Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on A Novel Treatment Paradigm for Successful Car T Immunotherapy Against Stroma-Rich Solid Tumors

Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023

No longer forecast to breakeven

Full year 2022 earnings released: US$1.99 loss per share (vs US$2.55 loss in FY 2021)

Now 20% undervalued after recent price drop

Cellectis S.A. has completed a Follow-on Equity Offering in the amount of $22 million.

A Look At The Intrinsic Value Of Cellectis S.A. (EPA:ALCLS)

Cellectis S.A. has completed a Follow-on Equity Offering in the amount of $22 million.

Now 35% undervalued

Cellectis S.A. announced that it has received $20 million in funding from Cytovia Therapeutics, Inc.

Cellectis S.A. announced that it has received $20 million in funding from Cytovia Therapeutics, Inc.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Now 22% undervalued

Insufficient new directors

Cellectis S.A. Announces the Resignation of Alain Godard as a Member of the Board

Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL

Cellectis S.A Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML

Third quarter 2022 earnings released: US$0.63 loss per share (vs US$0.82 loss in 3Q 2021)

Cellectis to Showcase Clinical Data from Ameli-01 and Preclinical Data from Ucartcs1 At Ash 2022

Cellectis S.A. to Report Q3, 2022 Results on Nov 03, 2022

Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022

Cellectis Appoints Mark Frattini as Chief Medical Officer

Consensus revenue estimates fall by 29%

Analyst Forecasts Just Became More Bearish On Cellectis S.A. (EPA:ALCLS)

Second quarter 2022 earnings released: US$0.42 loss per share (vs US$0.88 loss in 2Q 2021)

Cellectis S.A. Announces Executive Changes

Cellectis S.A. Announces U.S. Food and Drug Administration Clear Cellectis’ Investigational New Drug Application to Initiate A Phase 1/2A Clinical Trial of UCART20x22 for Patients

Cellectis S.A. to Report Q2, 2022 Results on Aug 04, 2022

Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors

Cellectis S.A., Annual General Meeting, Jun 28, 2022

Cellectis Presents Research Data on A Novel Immune-Evasive Universal CAR T-Cell At ASGCT

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cellectis S.A. to Report Q1, 2022 Results on May 12, 2022

Cellectis S.A. Releases Preclinical Data on Its Product Candidate UCART20x22 At the American Association for Cancer Research Annual Meeting

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cellectis S.A. to Report Q4, 2021 Results on Mar 03, 2022

Cellectis Appoints Bing C. Wang as Member of its Executive Committee

Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials

Is Cellectis (EPA:ALCLS) Using Too Much Debt?

Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting

Senior Vice President of Technical Operations - Europe Leopold Bertea has left the company

Third quarter 2021 earnings released: US$0.82 loss per share (vs US$0.71 loss in 3Q 2020)

Price target decreased to €20.50